U
CLDX icon

UBS’s Celldex Therapeutics CLDX Stock Holding History

UBS’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$735K Sell
3,783
-471
-11% -$103K ﹤0.01% 3888
2014
Q2 		$1.04M Sell
4,254
-103
-2% -$23.3K ﹤0.01% 3500
2014
Q1 		$1.16M Buy
4,357
+1,220
+39% +$467K ﹤0.01% 3345
2013
Q4 		$1.14M Sell
3,137
-1,214
-28% -$468K ﹤0.01% 3395
2013
Q3 		$2.31M Sell
4,351
-5,093
-54% -$1.75M ﹤0.01% 2434
2013
Q2 		$2.21M Buy
+9,444
New +$1.86M ﹤0.01% 2441

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 17.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

UBS's CLDX Position: Q3 2014 in Review

UBS reduced its Celldex Therapeutics (CLDX) stake by 11% in Q3 2014, selling an estimated $103K and leaving 3,783 shares worth $735K. The position accounts for ﹤0.01% of the portfolio, ranked #3888.

UBS first reported a position in CLDX in Q2 2013 and has held it in 6 quarters since. The position peaked at $2.31M in Q3 2013. 148 funds tracked by Wall St. Rank hold CLDX as of Q3 2014.

  • UBS held 3,783 shares of Celldex Therapeutics worth $735K as of Q3 2014.
  • UBS sold 471 Celldex Therapeutics shares in Q3 2014, an estimated $103K.
  • Celldex Therapeutics made up ﹤0.01% of UBS's portfolio in Q3 2014, its #3888 holding.
  • UBS first reported a position in Celldex Therapeutics in Q2 2013 and has held it in 6 quarters since.
  • UBS's Celldex Therapeutics position peaked at $2.31M in Q3 2013.
  • 148 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.